• No results found

University of Groningen Improving antimicrobial therapy for Buruli ulcer Omansen, Till Frederik

N/A
N/A
Protected

Academic year: 2021

Share "University of Groningen Improving antimicrobial therapy for Buruli ulcer Omansen, Till Frederik"

Copied!
3
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

University of Groningen

Improving antimicrobial therapy for Buruli ulcer

Omansen, Till Frederik

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date: 2019

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Omansen, T. F. (2019). Improving antimicrobial therapy for Buruli ulcer: Pre-clinical studies towards highly efficient, short-course therapy. University of Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

(2)

163 About the author

aBOuT The auThOr

Till Frederik Omansen was born on April 4th 1989 in Bückeburg, Germany. He grew up in the

Weserbergland area in Lower-Saxony, Germany. He attended high school at the Viktoria-Lu-ise-Gymnasium Hameln and the Humboldt-Gymnasium Bad Pyrmont, both in Germany and also spent some time at Rockford High School in Rockford, Michigan, USA in the framework of an international student exchange. Shortly after graduating from high school in 2008, Till moved to Brussels, Belgium to serve as a volunteer for one year in a neighborhood project for children and youths in an underprivileged area. He learned French and after completion of his volunteer service continued to give homework help and counselling to youths in the same organization, while studying biomedical sciences at the Catholic University of Louvain at the Brussels medical campus. In 2010 he enrolled in the International Bachelor of Medi-cine (IBMG), Global Health Profile at the University of Groningen in the Netherlands. During his time in Groningen, Till’s interest in tropical medicine and global health was sparked. He completed a 4-months research stay in Benin at the Buruli ulcer diagnosis and treat-ment center in Lalo. Till also attended the Junior Scientific Masterclass at the University of Groningen where he trained in research methods and acquired basic laboratory skills. These were applied in two student research projects on Staphylococcus aureus in the laboratory of molecular bacteriology at the University Medical Center Groningen. After completion of his B.Sc., Till travelled to Australia to spent a year at the Peter Doherty Institute for Infec-tion and Immunity at the University of Melbourne. During this time, he focused on in-vivo models of Buruli ulcer, transmission research and in-vitro drug testing. Back in Groningen, Till obtained a scholarship for combining his MD-training with a PhD at the University of Groningen. Based on prior experiences in Benin and equipped with laboratory skills from his work in Australia, a research curriculum addressing the need for a short-course therapy regimen for Buruli ulcer was chosen. During his PhD-research, Till completed two laboratory rotations at the Johns Hopkins Center for Tuberculosis in Baltimore, USA. There, he worked on in-vivo drug development for Buruli ulcer and tuberculosis. The curriculum was comple-mented with work at the Department of Control of Neglected Tropical Diseases at the World Health Organization headquarters in Geneva, where Till worked on the epidemiology of the neglected skin diseases Buruli ulcer, yaws and mycetoma. Till presented research at various international congresses in the Germany, the Netherlands, Switzerland, Austria and the USA and spent short research stays in Ghana and Sudan. His clinical training was conducted at the University Medical Center Groningen, the Netherlands and the European Medical School Oldenburg, Germany with electives in emergency medicine at the German Armed Forces Hospital Westerstede / Klinikzentrum Ammerland and in tropical medicine at the University Medical Center Hamburg-Eppendorf, both in Germany. Till graduated from his

(3)

164

About the author

MD in April 2018 and for participation in extracurricular activities was awarded his M.Sc. degree with honors. As of January 2019, Till follows a combined career as a researcher at the Bernhard Nocht Institute for Tropical Medicine with the Department of Clinical Trials and as a resident doctor at the I. Department of Medicine at the University Medical Center Hamburg-Eppendorf.

Referenties

GERELATEERDE DOCUMENTEN

The delayed healing following antimicrobial therapy of Buruli ulcer is believed to have led to an underappreciation of the value of antimicrobial in Buruli ulcer management in

Cotrimoxazol in the treatment of Mycobacterium ulcerans infection (Buruli ulcer) in west Africa. Espey DK, Djomand G, Diomande I, Dosso M, Saki MZ, Kanga J-M, et al. A pilot study

In this pilot study, we developed this idea further and tested IVIS® imaging of experimentally infected mice with the aim to refine the mouse tail model of Buruli ulcer and to

Following on from reports that avermectins have activity against Mycobacterium tuberculosis, we tested the in-vitro efficacy of ivermectin and moxidectin on M.. We observed

Accumulation observed as increasing trough concentrations after several days of IVM administration (FIG 1C) as well as the previously reported lipophilicity and accumulation

Figure 1: Median of footpad swelling grade of infected mouse footpads in response to treatment with high-dose rifamycins and clarithromycin.. Treatment was initiated 6 weeks

In this experiment, we compared the efficacy of these oxazolidinones, including a reduced dose of LZD, in combination with RIF to that of standard-of-care regimens based on their

ulcerans BALB/c mouse model that yielded high- dose rifampin as high-potential candidate regimen for further evaluation of future highly active, short-course regimen to treat BU,